Feb 21, 2008 - Sciele Pharma, Inc. (NASDAQ:SCRX) and LifeCycle Pharma A/S (OMX:LCP) today announced that Sciele has launched Fenoglide(TM) in the U.S. Fenoglide, indicated for the treatment of hyperlipidemia and hypertriglyceridemia, utilizes LifeCycle Pharma's Meltdose(R) technology, which is designed to provide enhanced absorption and greater bioavailability. Fenoglide will be available in 120-milligram and 40-milligram doses and will therefore have the lowest dosage strengths of fenofibrate available for patients.
Patrick Fourteau, chief executive officer of Sciele Pharma, Inc., said, "We are excited about the launch of Fenoglide, a product that incorporates LifeCycle Pharma's novel Meltdose technology. This is an important new product that will be marketed in the U.S. by Sciele Pharma's Primary Care Cardiovascular and Diabetes sales forces."
No comments:
Post a Comment